Navigation Links
Gq-coupled Receptor Assays Using FLEXstation

Alexander C. Zambon1, Bruce R. Conklin1, Laurence L. Brunton2,3, Paul A. Insel2,3, and Anne T. Ferguson4

1Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, CA 94141-9100
Departments of Pharmacology2 and Medicine3, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0636
4Molecular Devices Corp., 1311 Orleans Drive, Sunnyvale, CA 94089


Introduction
Gq-coupled receptors are cell-surface proteins that signal through multiple pathways, resulting in the release of Ca2+ from intracellular storage vesicles. They are gaining widespread popularity because they are implicated in critical intra- and intercellular processes. Since abnormal regulation of Gq-coupled receptor signaling pathways can cause various diseases, these receptors are prime targets for drug therapy. For this reason, it is important to study the regulation and specificity of Gq-coupled receptor activity.

Traditionally, Gq-coupled receptor activity is monitored by measuring an increase in intracellular inositol triphosphates (IP3) and/or calcium ions (Ca2+) (Fig. 1). Inositol phosphate measurement using [3H] inositol is labor intensive and requires radioactive waste storage and removal. In comparison, the release of calcium from intracellular stores into the cytoplasm was traditionally monitored in single cells by using fluorescence microscopy image analysis and a calcium-sensitive fluorescent dye. This procedure, while allowing a view of individual cells, is laborious and time-consuming when multiple ligands or drugs are being tested.


This application note describes the use of FLEXstation, a 96-well microplate fluorescence reader with fluid transfer capabilities, to measure the activity of the canine P2Y11 (cP2Y11) Gq-coupled receptor (1). The P2 superfamily of proteins includes the P2X family of ligand-gated ion channels and the P2Y family of G-coupled receptors (2). The P2Y receptors selectively respond to nucleotides and their analogs. To date, six subtypes have been cloned in various organisms, including human (3). All P2Y subtypes couple to phosphoinositide-Ca2+ pathway (4). Interestingly, P2Y11 mediates signaling through both phosphoinositide-Ca2+ and cAMP pathways (3, 4, 5, Fig. 1). This receptor plays a putative role in differentiation of immunocytes and renal disease (3, 6, 7, 8).

Here, we demonstrate that FLEXstation is an accurate, efficient, and rapid alternative to IP3 measurement in generating EC50 values for cP2Y11 agonists.


BACKGROUND
Cells.
The canine P2Y11 receptor was cloned by rapid amplification of cDNA ends (RACE) from the highly differentiated Madin-Darby canine kidney epithelial cell line MDCK-D1 (1, 9). The cP2Y11 gene was cloned into the retroviral expression vector pLXSN, which was used to transfect PA317 retroviral packing cells. The resulting virus was used to infect the canine thymocyte cell line CF2Th. Infected cells were exposed to 0.5 mg/mL G418 for at least 2 weeks. G418-resistant cells were used in subsequent experiments (1).

Characterization of cP2Y11 by phosphoinositide hydrolysis assay. The receptor was previously characterized, and its agonist selectivity profile is shown below:

Adenosine 5'-(2-O-thio) diphosphate (ADPβS) = 2-methylthioadenosine 5' diphosphate (2MT-ADP)>>ADP>ATP (1). The EC50 value for ADP was approximately 190 M as determined by phosphoinositide hydrolysis assay (1, Fig. 2).


MATERIALS
Characterization of cP2Y11 by Calcium Flux Assay

1. Cells: CF2Th canine thymocyte cells that stably overexpress the canine P2Y11 Gq-coupled receptor (1).

2. Reagents: FLEXstation Calcium Assay Kit (Molecular Devices, cat# R8041; Tel: 1-800-635-5577), ADP (Sigma, cat# A2754; Tel: 1-800-325-3010), probenecid (Sigma, cat# P8761).

3. Tissue culture microplates: 96-well, black-walled, clear-bottomed plates (Costar, cat# 3603; Tel: 1-800-492-1110).

4. Compound plates: 96-well, V-bottom clear polypropylene plates (E&K, cat# 651201; Tel: 408-378-2013).

5. Pipet tips: For FLEXstation: 200 L nonsterile, clear polypropylene tips (Molecular Devices, cat# 9000-0623).

6. Medium and buffers: Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum as previously described (9), trypsin-EDTA solution (Gibco/Invitrogen, cat# 25200-072; Tel: 1800-828-6686), Hank's balanced salt solution (HBSS) (10X) (Gibco, cat# 14065056; Tel: 1-800-828-6686), HEPES 1M buffer solution (Gibco, cat#15630-080).


METHODS
Cell Preparation
CF2Th cells were grown in DMEM supplemented with 10% heat-inactivated fetal calf serum. Cells were seeded the night before the experiment at a concentration of 2.55 x 104 cells/well in a volume of 100 L per well of a 96-well microplate. Cells were incubated at 37 C in 5% CO2 overnight.

Cell Loading Procedure
1X Reagent Buffer was prepared (1X HBSS/20 mM HEPES, pH 7.4) with the reagents described above. Loading buffer was prepared as described on the Molecular Devices web site (www.moleculardevices.com/pages/ reagent_lit.html).

Reagent Preparation
1. Prepare a fresh stock of 250 mM probenecid. Dissolve 710 mg of probenecid in 5 mL of 1M NaOH and then add 5 mL of 1X Reagent Buffer.

2. Add 1:50 dilution of 250 mM probenecid to the Loading Buffer (final concentration, 5 mM) and 1:100 dilution of 250 mM probenecid to 1X Reagent Buffer (final concentration, 2.5 mM). Probenecid inhibits endogenous efflux pumps that would prevent the dye from accumulating inside the cell.

3. Prepare a fresh stock of 5 mM ADP in 1X Reagent Buffer containing 2.5 mM probenecid. Prepare dilutions of ADP with 1X Reagent Buffer containing 2.5 mM probenecid (see Table 1).


Dye Loading of Cells
1. Add 100 L of Loading Buffer containing 5 mM probenecid to 100 L of cells that were plated the night before (final volume, 200 L/well).

2. Incubate cells for 0.5 h at 37 C.

3. In the meantime, prepare compound plates.


Compound Plate Preparation
Fifty microliters of ADP was added by FLEXstation to the 200 L already in the assay plate well. Since this was a 1/5 dilution, 5X stocks of ADP were made, starting with a 5 mM stock, which was subsequently diluted in series at 1:3 in 1X Reagent Buffer (see Table 1). Dead volume for the V-bottomed compound plates is less than 10 L, so keep this is mind when deciding the volume of compound to add. Each row of the compound plate contained 12 replicates of one concentration of ADP. Row A contained 1X Reagent Buffer alone (negative control), and rows B through H contained threefold dilutions of 1 mM ADP beginning with 1 mM ADP in row B as shown in Table 1.


SOFTmax PROSoftware Set Up

The assay parameters were as follows:

1. Wavelengths: The samples were excited at 485 nm, and emission was detected at 525 nm with a 515 nm cutoff filter.

2. Sensitivity: The number of reads/well was set to 6, and PMT was set to high.

3. Timing: Samples were read at 1.52 second intervals for 120 seconds (total of 79 reads/well).

4. Autocalibrate: On

5. Compound transfer: The pipettor height was set to 220 L to transfer a volume of 50 L at a rate of 4 (corresponds to a rate of 64 L/second). Compound transfer was started after 16 seconds of background reading.


RESULTS

The average EC50 value obtained with the FLEXstation Calcium Assay Kit and the FLEXstation was 47 mM (Figs. 3, 4). The values varied by less than twofold for experiments performed on the same day and by less than fourfold for experiments performed on different days. The range of values from all experiments was between 24 and 87 mM. The coefficient of variation of replicate samples within an experiment varied from 5.6 to 13.8% (average 8.6%) for the 1 mM ADP concentration.

Furthermore, the EC50 value obtained with the fluorescence-based whole cell method (47 M) compared favorably to the EC50 value obtained by measuring [3H]IP (~190 M). Thus, the assay is highly reproducible within and between experiments as well as between assay types (IP and calcium accumulation).



CONCLUSIONS
FLEXstation can be used to assess the specificity and sensitivity of Gq-coupled receptors for different ligands and drugs that are meant to target these receptors. Specifically, FLEXstation and SOFTmax PRO software provide easy experimental set-up, gathering of data and data analysis for development of calcium mobilization assays. Therefore, FLEXstation provides a useful tool for life science and drug discovery laboratories.


REFERENCES

1. Zambon, A. C., L. L. Brunton, K. E. Barrett, R. J. Hughes, B. Torres, and P. A. Insel. 2001. Cloning, expression, signaling mechanisms and membrane targeting of P2Y11 receptors in cultured MDCK-D1 cells. Mol. Pharmacol. 60: 2635.

2. Communi, D., R. Janssens, N. Suarez-Huerta, B. Robaye, and J. M. Boeynaems. 2000. Advances in signalling by extracellular nucleotides. The role and transduction mechanisms of P2Y receptors. Cell Signal. 12: 351360.

3. von Kugelgen, I., and A. Wetter. 2000. Molecular pharmacology of P2Yreceptors. Naunyn Schmiedebergs Arch. Pharmacol. 362: 310323.

4. Communi, D., C. Govaerts, M. Parmentier, and J. M. Boeynaems. 1997. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J. Biol. Chem. 272: 3196931973.

5. Communi, D., B. Robaye, and J. M. Boeynaems. 1999. Pharmacological characterization of the human P2Y11 receptor. Br. J. Pharmacol. 128: 11991206.

6. van der Weyden, L., A. D. Conigrave, and M. B. Morris. 2000. Signal transduction and white cell maturation via extracellular ATP and the P2Y11 receptor. Immunol. Cell. Biol. 78: 369374.

7. van der Weyden, L., D. J. Adams, and B. J. Morris. 2000. Capacity for purinergic control of renin promoter via P2Y(11) receptor and cAMP pathways. Hypertension 36: 10931098.

8. Communi, D., R. Janssens, B. Robaye, N. Zeelis, and J. M. Boeynaems. 2000. FEBS Letters 475: 3942.

9. Post, S. R., L. C. Rump, A. Zambon, R. J. Hughes, M. D. Buda, J. P. Jacobson, C. C. Kao, and P. A. Insel. 1998. ATP activates cAMP production via multiple purinergic receptors in MDCK-D1 epithelial cells. Blockade of an autocrine/ paracrine pathway to define receptor preference of an agonist. J. Biol. Chem. 273: 2309323097.


back to top


'"/>

Source:


Page: All 1 2 3 4 5 6 7

Related biology technology :

1. Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor
2. Gq-coupled receptor assays: a comparison of FLEXstation and FLIPR
3. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
4. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
5. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
6. Gene-Specific Primers for NMDA Receptor Subunits
7. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
8. Quantification of the Purinergic Receptor P2X3 using ICAT and Orthogonal 2D LC-MS/MS with an Ion Trap Mass Spectrometer
9. Isolation of Low Molecular Weight Digestion Products of the Human Platelet Thromboxane A2 Receptor, Rev A
10. Performance of Ad-A-Gene EGFP-Glucocorticoid Receptor (EGFP-GCCR): an adenoviral vector gene delivery system
11. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: coupled Receptor Assays Using FLEXstation

(Date:11/20/2008)...wswire-FirstCall/ -- Nephros, Inc. (Amex: NEP ),... filtration products for therapeutic applications,...provided an update on its operations and strategy...., , , Appointed James Scibetta Chair...rnest Elgin III President and CEO , Submitt...
(Date:11/20/2008)... Innovative consumer lifestyle and calorie manag...available through Dick,s Sporting Goods stores. ,...vember 20, 2008 -- BodyMedia, Inc. , a pioneer in...y announced the launch of GoWear® fit - a li...onsumers monitor their body and improve their heal...
(Date:11/20/2008)...swire/ -- IDRI (Infectious Disease Research,Insti... they have entered into,an agreement pursuant to ...exclusive license for the research, development, a...id Adjuvant (GLA) technology for products targetin...n to fight infectious diseases of,the developing ...
(Date:11/20/2008)... 20 Varian, Inc.,(Nasda... President and CEO,will speak at the Nasdaq OMX ...mber 4, 2008 at 9:45 a.m. Eastern time. , A... available from Varian,Inc.,s Web site at http:....com ,and click on "Investors." An archived repl...
Breaking Biology Technology:Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7BodyMedia, Inc. Launches GowearFit, the First Direct-to-Consumer Lifestyle and Calorie Management System 2BodyMedia, Inc. Launches GowearFit, the First Direct-to-Consumer Lifestyle and Calorie Management System 3IDRI and Immune Design Corp. Enter License Agreement on GLA Vaccine Adjuvant 2
...sletter featured your top picks of 2005 stories ba...t a selection of interesting stories you may have ...w is a great time to sign up. You,ll be e-mailed a...Thursdays. Sign up for your complementary subscri...ublishing schedule, both in our newsletters and on...
...al fix on January 10, following its normal "patch ... cautioned users about the unofficial patch, both ... have to be uninstalled when the official patch is...g affected has no other recourse until January 10....ill release an official patch for a dangerous Wind...
... on an official summary that referred to the bill ...n amendments. Under the law as enacted, the source...ns board. It would be analyzed in the case of a re...egrets the error and any confusion it may have cau...nor Jim Doyle signed into law on Wednesday will re...
...ained another $12 million in venture capital in an...aGen makes diagnostics products that clinicians an...mple, to determine the suitability of certain drug...ceived $21 million so far in venture investment, i... , ,The funding round was led by First Analysis C...
Other Biology Technology:Windows exploit worsens as stop-gap measures fill in for official patch 2Voting machine source code must be available for review 2
(Date:11/21/2008)...alkier, Department of Plant Biology and Biotechnol... Copenhagen, has been granted the Danisco Award 20...ellent research into secondary metabolites, which ...e, plants. In particular, her research has focuse...rt of glucosinolates in cruciferous plants. , T...
(Date:11/20/2008).../ -- DigitalPersona, Inc., the,leader in fingerpr...sona,Personal 4.0, an easy-to-use identity protec...siness users. DigitalPersona Personal 4.0 is the f... letting people use their fingerprints to,access ...ing, and other Web,sites -- to provide a critical...
(Date:11/20/2008)...am led by Thomas Schulthess of the U.S. Department...d the prestigious 2008 Association for Computing M...taining the fastest performance ever in a scientif...roup leader of ORNL,s Computational Materials Scie...ctor of the Swiss National Supercomputing Center a...
(Date:11/20/2008)...ing population, and turning research into commerci...($30.4 million) investment announced today by the ... (EPSRC), Technology Strategy Board (TSB) and the ...ncil (BBSRC). , This new investment will create ...fic breakthroughs have already been achieved. Thes...
Breaking Biology News(10 mins):The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen 2DigitalPersona Places Identity Protection at People's Fingertips 2DigitalPersona Places Identity Protection at People's Fingertips 3ORNL supercomputer simulation wins prize for fastest-running science application 2ORNL supercomputer simulation wins prize for fastest-running science application 3£20 million to fight virtual crime and treat our aging population 2£20 million to fight virtual crime and treat our aging population 3Mylan Restores Availability of Generic Levothyroxine in Florida 11381 1Mylan Restores Availability of Generic Levothyroxine in Florida 11381 2MBF Healthcare Acquisition Corp to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings 11379 1MBF Healthcare Acquisition Corp to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings 11379 2MBF Healthcare Acquisition Corp to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings 11379 3MBF Healthcare Acquisition Corp to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings 11379 4Natural Alternatives International Inc Announces Second Quarter Results 11377 1Natural Alternatives International Inc Announces Second Quarter Results 11377 2Natural Alternatives International Inc Announces Second Quarter Results 11377 3Natural Alternatives International Inc Announces Second Quarter Results 11377 4Natural Alternatives International Inc Announces Second Quarter Results 11377 5Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 1Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 2Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 3Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 4Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 5Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 6Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 7Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 8Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 9Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 10Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 11Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 12Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 13Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 14Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 15Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 16Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 17Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 18Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 19Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 20Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 21Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 22Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 23Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 24Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 25Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 26Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 27Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 28Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 29
...esearchers from the University of Verona and the I... pivotal role played by Cytomegalovirus infection ...lerosis is the main cause of morbidity and mortali...ng, diabetes, hypertension and high cholesterol le...genesis of the disease that also recognises a gene...
...g used in emergency rooms to treat methamphetamine...ain known to regulate movement, a new study shows....s, indicate that only the combination of the medic... destructive effects, not either one alone. Senior...n University School of Medicine suspect the damage...
...eaning to watching out for other mothers, kids. ...eer conducted by the University of Alberta in Edmo...o in Canada, showed that both species responded to...the responses elicited when coyotes attack fawns, ...l and mule deer calls, even when their own fawn st...
...om the National Institutes of Health (NIH), resear...veloping a physics-based virtual model that can si...ed in conjunction with existing 3-D models, adding...improve the accuracy and effectiveness of radiatio...rge Xu, professor of nuclear and biomedical engine...
Other Biology News:Cytomegalovirus exacerbates atherosclerosis through an autoimmune mechanism 2Common treatment for methamphetamine overdose may damage brain cells 2Mule deer moms rescue other fawns 2'Virtual Patient' to simulate real-time organ motions for radiation therapy 2
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL
ZOOM® IEF Fractionator from Invitrogen
...ased mounting medium for immunohistology. It is de...f peroxidase and alkaline phosphatase stained tiss...ent optical characteristics. Crystal / Mount is th...ong-term storage of antigens localized with organi...
Biology Products: